These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 22577776)

  • 21. Pimecrolimus 1% cream for the treatment of atopic dermatitis.
    Wolff K
    Skin Therapy Lett; 2005 Oct; 10(8):1-6. PubMed ID: 16292456
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Topical immunomodulators, such as tacrolimus and pimecrolimus, in the treatment of atopic dermatitis].
    de Bruin-Weller MS; Bruijnzeel-Koomen CA
    Ned Tijdschr Geneeskd; 2005 May; 149(20):1096-100. PubMed ID: 15932135
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pimecrolimus cream (1%) efficacy in perioral dermatitis - results of a randomized, double-blind, vehicle-controlled study in 40 patients.
    Oppel T; Pavicic T; Kamann S; Bräutigam M; Wollenberg A
    J Eur Acad Dermatol Venereol; 2007 Oct; 21(9):1175-80. PubMed ID: 17894701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and efficacy of early intervention with pimecrolimus cream 1% combined with corticosteroids for major flares in infants and children with atopic dermatitis.
    Siegfried E; Korman N; Molina C; Kianifard F; Abrams K
    J Dermatolog Treat; 2006; 17(3):143-50. PubMed ID: 16854753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of pimecrolimus cream 1% in the treatment of patients with atopic dermatitis who demonstrate a clinical insensitivity to topical corticosteroids: a randomized, multicentre vehicle-controlled trial.
    Leung DY; Hanifin JM; Pariser DM; Barber KA; Langley RG; Schlievert PM; Abrams B; Hultsch T
    Br J Dermatol; 2009 Aug; 161(2):435-43. PubMed ID: 19416245
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Innovative use of topical calcineurin inhibitors.
    Lin AN
    Dermatol Clin; 2010 Jul; 28(3):535-45. PubMed ID: 20510763
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A bilateral comparison study of pimecrolimus cream 1% and a topical medical device cream in the treatment of patients with atopic dermatitis.
    Emer JJ; Frankel A; Sohn A; Lebwohl M
    J Drugs Dermatol; 2011 Jul; 10(7):735-43. PubMed ID: 21720655
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.
    Murrell DF; Calvieri S; Ortonne JP; Ho VC; Weise-Riccardi S; Barbier N; Paul CF
    Br J Dermatol; 2007 Nov; 157(5):954-9. PubMed ID: 17935515
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study of the Atopic March: Development of Atopic Comorbidities.
    Schneider L; Hanifin J; Boguniewicz M; Eichenfield LF; Spergel JM; Dakovic R; Paller AS
    Pediatr Dermatol; 2016 Jul; 33(4):388-98. PubMed ID: 27273433
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Review of pimecrolimus cream 1% for the treatment of mild to moderate atopic dermatitis.
    Hebert AA
    Clin Ther; 2006 Dec; 28(12):1972-82. PubMed ID: 17296454
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of 1% pimecrolimus cream among infants: experience with 1133 patients treated for up to 2 years.
    Paul C; Cork M; Rossi AB; Papp KA; Barbier N; de Prost Y
    Pediatrics; 2006 Jan; 117(1):e118-28. PubMed ID: 16361223
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy and safety of pimecrolimus cream 1% in adults with moderate atopic dermatitis.
    Meurer M; Fartasch M; Albrecht G; Vogt T; Worm M; Ruzicka T; Altmeyer PJ; Schneider D; Weidinger G; Braeutigam M;
    Dermatology; 2004; 208(4):365-72. PubMed ID: 15178928
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Pimecrolimus and vaccinations].
    Schmutz JL; Barbaud A; Tréchot P
    Ann Dermatol Venereol; 2007; 134(6-7):598. PubMed ID: 17702119
    [No Abstract]   [Full Text] [Related]  

  • 34. Allergic contact dermatitis from pimecrolimus in a patient with tacrolimus allergy.
    Shaw DW; Maibach HI; Eichenfield LF
    J Am Acad Dermatol; 2007 Feb; 56(2):342-5. PubMed ID: 17141361
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eczema drugs tacrolimus (Protopic) and pimecrolimus (Elidel): cancer concerns.
    Wooltorton E
    CMAJ; 2005 Apr; 172(9):1179-80. PubMed ID: 15817641
    [No Abstract]   [Full Text] [Related]  

  • 36. Pharmacokinetics of topical calcineurin inhibitors in adult atopic dermatitis: a randomized, investigator-blind comparison.
    Draelos Z; Nayak A; Pariser D; Shupack JL; Chon K; Abrams B; Paul CF
    J Am Acad Dermatol; 2005 Oct; 53(4):602-9. PubMed ID: 16198779
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pimecrolimus is safe and effective in treating atopic dermatitis.
    Eichenfield DZ; Eichenfield LF
    J Pediatr; 2015 Nov; 167(5):1171-2. PubMed ID: 26603713
    [No Abstract]   [Full Text] [Related]  

  • 38. Topical calcineurin inhibitors for atopic dermatitis: balancing clinical benefit and possible risks.
    Qureshi AA; Fischer MA
    Arch Dermatol; 2006 May; 142(5):633-7. PubMed ID: 16702502
    [No Abstract]   [Full Text] [Related]  

  • 39. [Therapy of atopic eczema with calcineurin inhibitors].
    Luger TA; Bieber T; Meurer M; Mrowietz U; Schwarz T; Simon J; Werfel T; Zuberbier T
    J Dtsch Dermatol Ges; 2005 May; 3(5):385-91. PubMed ID: 16372807
    [No Abstract]   [Full Text] [Related]  

  • 40. Different effects of pimecrolimus and betamethasone on the skin barrier in patients with atopic dermatitis.
    Jensen JM; Pfeiffer S; Witt M; Bräutigam M; Neumann C; Weichenthal M; Schwarz T; Fölster-Holst R; Proksch E
    J Allergy Clin Immunol; 2009 May; 123(5):1124-33. PubMed ID: 19410693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.